Infectio, 2020 Objective: To evaluate the cost-effectiveness of ceftolozane/tazobactam + metronidazole (C/T+M) and ceftolozane/tazobactam (C/T) compared with 8 alternatives used in the treatment of complicated intraabdominal infection (cIAI) and complicated urinary ...
Fabián Hernández
doaj +1 more source
Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan‐resistant Pseudomonas aeruginosa [PDF]
, 2015 The treatment of chronic Pseudomonas aeruginosa infections is challenging, with resistance and antibiogram diversity accumulating during successive therapies.
Andrews +9 more
core +1 more source
Targeting <i>Pseudomonas aeruginosa</i> resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusion. [PDF]
Antimicrob Agents ChemotherCeftolozane/tazobactam is a key antibiotic for Pseudomonas aeruginosa infections. Our objective was to determine whether continuous infusion (CI) of ceftolozane/tazobactam can achieve aggressive pharmacokinetic/pharmacodynamic (PK/PD) targets that ...
Cojutti PG +7 more
europepmc +2 more sources
A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar? [PDF]
J Antimicrob ChemotherObjectives To assess the clinical usefulness of a therapeutic drug monitoring (TDM)-guided strategy for attaining an aggressive pharmacokinetic/pharmacodynamic (PK/PD) target of continuous infusion (CI) ceftolozane/tazobactam monotherapy in patients ...
Gatti M +8 more
europepmc +2 more sources
Multi-drug resistant Gram-negative bacteria: antibiotic-resistance and new treatment strategies [PDF]
, 2017 In this editorial, we treat the multi-drug-resistance of microorganisms such as Klebsiella pneumonia (Kp) and Acinetobacter baumanii and the issues concerning the management of these infections.
Angelis, Massimiliano De +2 more
core +1 more source
Microbiology Spectrum, 2023 Ceftolozane/tazobactam is approved for the treatment of patients from birth to
Emmanuel Roilides +7 more
doaj +1 more source
Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant Escherichia coli With Tigecycline Monotherapy [PDF]
, 2020 We present a successful treatment, with tigecycline monotherapy, of acute prostatitis caused by multidrug-resistant Escherichia coli harboring an NDM-1 carbapemenase along with a CMY-2 cephalosporinase and a TEM ...
Babouee Flury, Baharak +7 more
core +2 more sources
Journal of Infection in Developing Countries, 2020 Introduction: In view of the continuous rise in Gram-negative bacterial resistance and limited treatment options, Ceftolozane/tazobactam (C/T) is a newly introduced antimicrobial agent in Lebanon for its demonstrated activity against resistant Gram ...
George F Araj +3 more
doaj +1 more source
Antibiotics, 2022 Ceftazidime–avibactam and ceftolozane–tazobactam are approved for the treatment of complicated Gram-negative bacterial infections including multidrug-resistant (MDR) Pseudomonas aeruginosa.
Mazen A. Sid Ahmed +10 more
doaj +1 more source
The Surgical Infection Society revised guidelines on the management of intra-abdominal infection [PDF]
, 2017 Background: Previous evidence-based guidelines on the management of intra-abdominal infection (IAI) were published by the Surgical Infection Society (SIS) in 1992, 2002, and 2010. At the time the most recent guideline was released, the plan was to update
Chang, Phillip K +11 more
core +3 more sources